Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

Ähnliche Einträge

• EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
  von: Xu, Jianlin, et al.
  Veröffentlicht: (2016)
• The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
  von: Xu, Jianlin, et al.
  Veröffentlicht: (2016)
• Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
  von: Xu, Jianlin, et al.
  Veröffentlicht: (2016)
• Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
  von: Lou, Yuqing, et al.
  Veröffentlicht: (2021)
• Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs
  von: Zhang, Hai, et al.
  Veröffentlicht: (2020)